An article titled, ‘Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis‘ was published in December 2025 in the eJHaem.
This is an important study for MPN patients.
It recognised that ‘As patients with MPNs often require lifelong treatment, understanding the long-term implications of ruxolitinib therapy is crucial for optimising patient care and risk management strategies.’
It investigated patients with long term ruxolitinib use for cases of ‘non-melanoma skin cancer (NMSC), other secondary malignancies and infections (zoster, urinary tract infection, pneumonia and sepsis)’.
The findings of the study ‘suggest that extended ruxolitinib therapy is associated with specific long-term risks, particularly NMSC (non melanoma skin cancer) and zoster (shingles) reactivation, while not increasing the incidence of secondary malignancies. These results support continued vigilance and preventive strategies in the setting of long-term ruxolitinib exposure.’
The full article is free to access and available at the link below.
Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis
